Biography

The main focus of our research is the use of antisense oligonucleotides (AOs) for splice-switching correction in inherited diseases. Our lab developed the first AO approved by the FDA for the treatment of Duchenne muscular dystrophy (Exondys-51), and we endeavour to extend this strategy to treat other rare genetic disorders.

I have recently started a part-time PhD at Murdoch University while working as a Research Officer. My project is titled "Antisense Oligonucleotide-Mediated Precision Treatment for Collagenopathy". I hope to develop a therapeutic strategy for the treatment of recessive dystrophic epidermolysis bullosa. 

Featured